Two parallel phase 3 trials—STOP‑V1 and STOP‑V2—randomized adults with moderate-to-severe nonsegmental vitiligo to once-daily povorcitinib 30 mg or placebo. The studies were double-blind and placebo-controlled, with primary outcomes reported at 52 weeks. STOP‑V1 enrolled 467 participants and STOP‑V2 enrolled 449, the authors noted. The trials targeted patients considered candidates for systemic therapy under contemporary severity definitions, reflecting disease extent, activity and lesion visibility.
The source specified adult enrollment criteria; it did not report data for adolescents or for patients with segmental vitiligo. Baseline demographic or stratification details beyond overall enrollment numbers were not provided in the summary, and the report did not include additional dosing arms in these phase 3 trials beyond the once-daily 30 mg regimen described.
Both studies used a prespecified primary endpoint of ≥75% improvement in the facial Vitiligo Area Scoring Index (F‑VASI75) at week 52. Investigators reported that this endpoint was met in each trial, with povorcitinib producing statistically significant repigmentation versus placebo.
STOP‑V1 results: 18.9% of participants receiving povorcitinib achieved F‑VASI75 versus 6.8% of participants on placebo; the study team reported an odds ratio of 3.1 (95% CI 1.6–5.9; P = 0.0003). STOP‑V2 mirrored the absolute povorcitinib response rate but showed a lower placebo response: 18.9% versus 3.1% (odds ratio 7.5; 95% CI 3.0–18.6; P < 0.0001). The authors framed these differences as both statistically significant and clinically meaningful repigmentation with povorcitinib.
The summary emphasized facial repigmentation as the primary outcome. The source also referenced earlier phase 2 dose-ranging data showing numerical improvements in facial and total body repigmentation across multiple doses; however, full phase 2 details and T‑VASI (total VASI) measures from the phase 3 dataset were not enumerated in the provided text.
Tolerability across both trials was described as similar between povorcitinib and placebo arms. The percentage of patients reporting any treatment‑emergent adverse event (TEAE) was close in both groups: STOP‑V1/STOP‑V2 reported TEAEs for povorcitinib versus placebo as 68.7%/66.7% versus 63.7%/62.7%, respectively.
The most common TEAEs with povorcitinib were nasopharyngitis (STOP‑V1/STOP‑V2: 11.2%/11.3% versus placebo 9.8%/11.1%), acne (10.7%/10.8% versus placebo 3.0%/2.2%), and upper respiratory tract infection (6.9%/14.0% versus placebo 9.0%/10.7%). Serious TEAEs were generally isolated single events, and the trial reports indicated that Janus kinase inhibitor class‑specific adverse events were absent or rare in these 52‑week data.
The summary did not provide detailed severity grading, time-to-onset distributions, or laboratory-safety summaries in the text provided. Long-term safety beyond 52 weeks was not reported in the source material summarized here.
The authors reiterated that JAK–STAT signaling contributes to vitiligo pathogenesis by promoting CXCL10 production and recruitment of cytotoxic CD8+ T cells that mediate melanocyte loss. That mechanistic framework provided the rationale for targeting JAK1 with an oral, selective inhibitor. The source noted that topical ruxolitinib (a JAK1/JAK2 inhibitor) was previously approved for repigmentation in NSV and is indicated for patients aged 12 years and older for localized topical treatment up to 10% body surface area.
Povorcitinib, described in the report as an oral, highly selective JAK1 inhibitor, showed dose-dependent effects in earlier phase 2 dose-ranging work; in that phase 2 study, multiple once-daily doses improved facial and total body repigmentation versus placebo at six months. The phase 3 results build on that efficacy signal for systemic therapy in adults with more extensive disease.
The investigators and authors reported primary 52‑week outcomes, but the source did not report longer-term follow-up beyond that time point in the provided summary. The trials enrolled adults; efficacy and safety in adolescents were not reported here. The summary did not present head-to-head comparisons with topical ruxolitinib or other systemic agents, nor did it include granular safety laboratory results, durability of response after treatment cessation, or detailed subgroup analyses in the text provided.
ClinicalTrials.gov identifiers were provided (NCT06113445 and NCT06113471), offering access to full protocols and extended data; those repositories will be needed to resolve unanswered questions about longer-term safety, comparative effectiveness and specific subgroup responses. The report concluded that once-daily povorcitinib 30 mg achieved higher F‑VASI75 rates than placebo at 52 weeks and was generally well tolerated in adults with moderate-to-severe NSV, while noting remaining uncertainties that require additional data.